Ribas

Suzano to Invest R$14.7 Billion in a New Pulp Plant in Mato Grosso do Sul

Retrieved on: 
Wednesday, May 12, 2021
Environment, Forest Products, Manufacturing, Agriculture, Natural Resources, Other Manufacturing, Ribas, Pardo River

The unit will be built in the municipality of Ribas do Rio Pardo, in Mato Grosso do Sul state, and should start production by the end of the first quarter of 2024.

Key Points: 
  • The unit will be built in the municipality of Ribas do Rio Pardo, in Mato Grosso do Sul state, and should start production by the end of the first quarter of 2024.
  • The project estimates industrial investments of R$14.7 billion, making it one of the largest private-sector investments currently under development in Brazil.\nThe initiative, called \xe2\x80\x9cCerrado Project\xe2\x80\x9d, will expand Suzano\xe2\x80\x99s current pulp production capacity, of 10.9 million tons, by approximately 20%.
  • The industrial unit in Ribas do Rio Pardo also will be the company\xe2\x80\x99s most competitive.\n\xe2\x80\x9cThe new plant represents an important advance in our long-term strategy.
  • The plant will have the capacity to sell approximately 180 MWave of surplus energy to Brazil\xe2\x80\x99s power grid.

Arcus Biosciences Appoints Internationally Distinguished Physician-Scientist, Antoni Ribas, M.D., Ph.D., to Board of Directors

Retrieved on: 
Monday, October 28, 2019
Biotechnology, Pharmaceutical, Health, Oncology, Arcus, Ribas, Kite Pharma, Companies

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Antoni Ribas, M.D., Ph.D. has joined the Companys Board of Directors.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Antoni Ribas, M.D., Ph.D. has joined the Companys Board of Directors.
  • Dr. Ribas has founded or advised several successful biopharma companies in addition to Arcus, such as Kite Pharma and Flexus Biosciences.
  • Dr. Ribas has been a member of the Arcus Scientific Advisory Board since its creation in 2015.
  • Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Agilent Presents Thought Leader Award to Professor Antoni Ribas

Retrieved on: 
Friday, April 12, 2019
Technology, Software, Health, Biotechnology, Genetics, Oncology, Pharmaceutical, Research, Science, Agilent Technologies, Hewlett-Packard, Ribas, Companies, California

Agilent Technologies Inc. (NYSE: A) today announced that Professor Antoni Ribas has received an Agilent Thought Leader Award in support of his genomics and immunotherapy research.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that Professor Antoni Ribas has received an Agilent Thought Leader Award in support of his genomics and immunotherapy research.
  • Dr. Ribas is a professor of medicine and surgery as well as molecular and medical pharmacology at the University of California at Los Angeles (UCLA).
  • Im very honored to receive this award and be given the opportunity to further my research on the deadliest form of skin cancer, said Dr. Ribas.
  • The Agilent Thought Leader Program promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space.